What is Metriport?
Founded in 2022 by Dima Goncharov and Colin Elsinga, Metriport provides a robust, open-source framework designed to streamline the extraction and standardization of complex medical data. The platform functions as a comprehensive middleware layer, enabling clinicians and health-tech developers to access a unified view of patient history through seamless EHR integrations. By automating the deduplication and enrichment of records, Metriport effectively reduces the administrative burden on healthcare organizations while enhancing the quality of clinical decision-making. Its market position is defined by a commitment to transparency and interoperability, addressing the long-standing technical debt inherent in legacy medical data systems.
How much funding has Metriport raised?
Metriport has raised a total of $28.4M across 2 funding rounds:
Angel/Seed
$2.4M
Unspecified
$26M
Angel/Seed (2022): $2.4M with participation from Leonis Investissement, Triple Impact Capital, Nueterra Capital, Y Combinator, Zillionize, and MyAsiaVc
Unspecified (2026): $26M led by Y Combinator, Artis Ventures Management Iii, and TJ Parker
Key Investors in Metriport
Y Combinator
Established in 2005 and located in Mountain View, California, Y Combinator provides seed funding for startup businesses and to gauge investors for businesses.
Artis Ventures Management Iii
Artis Ventures is a dedicated venture capital fund focused on Tech Bio+Health, investing in innovative data-driven life sciences companies that aim to enhance human health and wellness.
Nueterra Capital
Nueterra Capital focuses on investing in the integration of healthcare and technology, aiming to empower the next generation of start-ups through strategic resources and guidance.
What's next for Metriport?
With the recent capital injection, Metriport is expected to scale its engineering efforts and expand its footprint within the enterprise healthcare sector. The strategic focus will likely shift toward deepening its integration capabilities and enhancing the scalability of its data processing pipelines to accommodate larger health systems. As the company matures, it will continue to leverage its open-source roots to foster a developer-centric ecosystem, ensuring that its infrastructure remains the standard for medical data exchange. Future growth will be driven by the increasing necessity for AI-ready, clean data sets in clinical research and personalized medicine, positioning Metriport as a foundational player in the digital health transformation.
See full Metriport company page
